Tracking MS Medication's impact on unborn babies

NCT ID NCT06433765

Recruiting now Knowledge-focused Sponsor: TG Therapeutics, Inc. Source: ClinicalTrials.gov ↗

Summary

This study aims to understand if the multiple sclerosis medication BRIUMVI affects pregnancy outcomes. Researchers will compare birth defect rates between pregnant women with MS who take BRIUMVI and those who don't. The registry will follow 728 participants to collect safety information about medication use during pregnancy.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

BRIUMVI® Pregnancy Registry Virtual Research Coordination Center
RECRUITING

Wilmington, North Carolina, 28401-3331, United States

Conditions

Explore the condition pages connected to this study.

MULTIPLE SCLEROSIS